Xilio Therapeutics, Inc. Income Tax Expense
Xilio Therapeutics, Inc. (XLO) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-23
- Xilio Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-12-31 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-09-30 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-06-30 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-03-31 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for fiscal 2023 was $0.00.
- Xilio Therapeutics, Inc. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 5 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 derived: sum of 4 quarters · filed 2023-03-02 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 derived: sum of 4 quarters · filed 2023-03-02 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-12-02 | ||||
| 2020-05-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |